← Back to feed

Valirx

VAL · AIM · Health Care · mcap £1.8m today

All announcements

All RNS · 31 Key events · 22

15 Sep 26

Half-year Results Net cash ≈ market cap

HALF YEARLY REPORT FOR THE PERIOD ENDED 30 JUNE 2026
RNS 9771482 ↗
10 Aug 26

Cytolytix Patent Update

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, is pleased to provide the following updates on its majority owned subsidiary Cytolytix Limited ("Cytolytix").
RNS 9711872 ↗
17 Jul 26

Result of AGM, Warrants & Directorate Change
RNS 9675147 ↗
22 Jun 26

Conclusion of Evaluation with University of Dundee

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health provides the following update at the conclusion of the Evaluation Agreement with the University of Dundee and their Drug Discovery...
RNS 9628752 ↗
22 Jun 26

Final Results & Notice of AGM Strategic review

London, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, announces its audited results for the year ended 31 December 2025.
RNS 9628668 ↗
02 Jun 26

Conclusion of Evaluation with Stingray

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health provides the following update at the conclusion of the Evaluation Agreement with Stingray Bio Limited ("Stingray") announced on 5 August 2025.
RNS 9596020 ↗
01 Jun 26

ValiRx Exercises Option on Evaluation Asset

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health is pleased to provide the following update on its evaluation agreement with The Royal Institute for the advancement of Learning /...
RNS 9593425 ↗
27 May 26

Cytolytix Patent Granted

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health is pleased to provide the following updates on its majority owned subsidiary Cytolytix Limited ("Cytolytix").
RNS 9586505 ↗
21 May 26

Result of Oversubscribed WRAP Retail Offer

London, UK - ValiRx Plc (AIM: VAL), an innovative life sciences company focusing on early-stage cancer therapeutics and women's health, with a pipeline of assets including CLX001 and VAL201, is pleased to confirm, further to the announcement made on 18 May...
RNS 9578799 ↗
18 May 26

WRAP Retail Offer for up to £150,000

London, UK - ValiRx Plc (AIM: VAL), an innovative life sciences company focusing on early-stage cancer therapeutics and women's health, with a pipeline of assets including CLX001 and VAL201, is pleased to announce a retail offer via the Winterflood Retail...
RNS 9572063 ↗
15 May 26

Fundraising of up to £1,155,000

for in-licensing, IP portfolio expansion, preclinical development and expansion of ValiRx Animal Health
RNS 9569673 ↗
31 Mar 26

Change of Registered Office
RNS 9500614 ↗
26 Mar 26

ValiRx Commercial Update Q1 2026

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health is pleased to share a commercial update for Q1 2026 against the objectives and milestones for 2026.
RNS 9492519 ↗
24 Mar 26

ValiRx and TwinEdge to present Digital Twin data

ValiRx and TwinEdge to present Digital Twin data
RNS 9487952 ↗
04 Mar 26

Director/PDMR Shareholding Director buys

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, announces that it received notification on 3 March 2026 that Mark Eccleston, Chief Executive Officer, made the following purchase of...
RNS 9456983 ↗
02 Mar 26

ValiRx forms ValiRx Animal Health Ltd subsidiary

ValiRx sets up wholly owned Subsidiary ValiRx Animal Health LTD
RNS 9452345 ↗
19 Jan 26

Exercise of Warrants

ValiRx plc (the "Company") (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health announces it has received notification for the exercise of warrants over 80,000 ordinary shares in the Company at an exercise...
RNS 9363972 ↗
09 Jan 26

Evaluation and Transfer Agreement

The following amendment has been made to the 'New Evaluation and Material Transfer Agreement' announcement released on 9 January 2026 at 7:00 a.m. under RNS No 2552O.
RNS 9344777 ↗
09 Jan 26

New Evaluation and Material Transfer Agreement

ValiRx plc (the "Company") (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health and The Royal Institute for the Advancement of Learning/McGill University ("McGill"), a Canadian based University, and The...
RNS 9342867 ↗
08 Jan 26

Holding(s) in Company
RNS 9341995 ↗
05 Dec 25

Holding(s) in Company
RNS 9278671 ↗
24 Nov 25

Holding(s) in Company
RNS 9253938 ↗
24 Nov 25

Holding(s) in Company
RNS 9253020 ↗
20 Nov 25

Result of GM & Issue of Equity

London, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, announces that, further to the announcement on 4 November 2025, at the Company's General Meeting held earlier today, all resolutions...
RNS 9247145 ↗
13 Nov 25

Holding(s) in Company
RNS 9232098 ↗
10 Nov 25

Holding(s) in Company
RNS 9222242 ↗
04 Nov 25

Posting of Circular and Notice of General Meeting
RNS 9212318 ↗
04 Nov 25

Result of WRAP Retail Offer

ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, is pleased to confirm, further to the announcements made on 30 October 2025, the result of WRAP Retail Offer at the Issue Price of 0.25 pence per share.
RNS 9210161 ↗
30 Oct 25

WRAP Retail Offer for up to £300,000

ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, is pleased to announce a retail offer via the Winterflood Retail Access Platform ("WRAP") to raise up to £300,000 (the "WRAP Retail Offer")...
RNS 9203542 ↗
30 Oct 25

Fundraising of up to £1,050,000

Conditional Placing of 183,695,400 Tranche 2 Placing Shares
RNS 9203538 ↗
14 Oct 25

Inaphaea Commercial update

London, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, is pleased to provide the following updates on its wholly owned subsidiary Inaphaea Limited ("Inaphaea").
RNS 9168690 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.